Blocking FDA approval of abortion pill could stifle innovation in the biopharma industry, experts say

  • 📰 CNBC
  • ⏱ Reading Time:
  • 52 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 24%
  • Publisher: 72%

Deutschland Nachrichten Nachrichten

Deutschland Neuesten Nachrichten,Deutschland Schlagzeilen

A complicated legal fight over abortion pill mifepristone could reduce innovation in the biopharma industry, companies and experts in law and economics said.

The Justice Department will seek emergency intervention from the U.S. Supreme Court, it said Thursday.

That outcome would bring uncertainty to a regulatory framework that drugmakers rely on during the expensive and lengthy process of developing medications, they told CNBC. He said that kind of legal fight could have an effect similar to that of a drug's patent expiring, which reduces the medication's time on the market and typicallyA potential legal challenge is a "risk that effectively reduces the economic incentives of bringing drugs to the market," Lakdawalla said. He said it could cause companies and investors to funnel less money into drug research and development.

It takes at least 10 years on average for a new drug to reach the marketplace after its initial discovery, according to, the primary lobbying arm of the pharmaceutical industry. Clinical trials alone take six to seven years on average. Hastings was among the biopharma executives who first issued the open letter. He said the industry is "going to have trouble" if Kacsmaryk's ruling is ultimately upheld.

 

Vielen Dank für Ihren Kommentar.Ihr Kommentar wird nach Prüfung veröffentlicht.
Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen:

 /  🏆 12. in DE

Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen